MX2008002294A - Pyrimidine derivatives and their use as kcnq potassium channels openers. - Google Patents
Pyrimidine derivatives and their use as kcnq potassium channels openers.Info
- Publication number
- MX2008002294A MX2008002294A MX2008002294A MX2008002294A MX2008002294A MX 2008002294 A MX2008002294 A MX 2008002294A MX 2008002294 A MX2008002294 A MX 2008002294A MX 2008002294 A MX2008002294 A MX 2008002294A MX 2008002294 A MX2008002294 A MX 2008002294A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrimidine derivatives
- potassium channels
- kcnq potassium
- openers
- channels openers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pyrimidine derivatives of the general formula I or salts thereof and their use as openers of the KNCQ family potassium ion channels, particularly in the treatment of epilepsy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200501262 | 2005-09-09 | ||
PCT/DK2006/050039 WO2007065449A1 (en) | 2005-09-09 | 2006-09-07 | Pyrimidine derivatives and their use as kcnq potassium channels openers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008002294A true MX2008002294A (en) | 2008-03-14 |
Family
ID=37199174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008002294A MX2008002294A (en) | 2005-09-09 | 2006-09-07 | Pyrimidine derivatives and their use as kcnq potassium channels openers. |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1937653A1 (en) |
JP (1) | JP2009507052A (en) |
KR (1) | KR20080043314A (en) |
CN (1) | CN101258133A (en) |
AR (1) | AR055420A1 (en) |
AU (1) | AU2006322461A1 (en) |
BR (1) | BRPI0615631A2 (en) |
CA (1) | CA2621854A1 (en) |
EA (1) | EA200800780A1 (en) |
IL (1) | IL189545A0 (en) |
MX (1) | MX2008002294A (en) |
NO (1) | NO20081713L (en) |
UA (1) | UA93387C2 (en) |
WO (1) | WO2007065449A1 (en) |
ZA (1) | ZA200802174B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201070189A1 (en) * | 2007-08-01 | 2010-08-30 | Х. Лундбекк А/С | USE OF COMPOUNDS, OPENING KCNQ CALIUM CHANNELS, TO SUPPRESS SYMPTOMS OR TREATMENT OF DISORDERS OR CONDITIONS, WHICH DOPAMINERGICAL SYSTEM IS DAMAGED |
US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
WO2010097379A1 (en) * | 2009-02-24 | 2010-09-02 | Neurosearch A/S | Substituted pyrimidin derivatives and their medical use |
MX2013000138A (en) * | 2010-07-08 | 2013-03-05 | Pfizer | Piperidinyl pyrimidine amides as kv7 potassium channel openers. |
AU2011317855B2 (en) * | 2010-10-20 | 2015-04-30 | Grunenthal Gmbh | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators |
CN103508943B (en) * | 2012-06-29 | 2017-06-09 | 江苏先声药业有限公司 | As the compound of potassium channel modulating agents |
CN103508960B (en) * | 2012-06-29 | 2017-12-12 | 江苏先声药业有限公司 | Benzheterocyclic derivatives |
BR112017008178A2 (en) * | 2014-10-24 | 2017-12-19 | Ono Pharmaceutical Co | kcnq2-5 channel activator |
WO2021023616A1 (en) * | 2019-08-02 | 2021-02-11 | H. Lundbeck A/S | Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005508833A (en) * | 2001-02-20 | 2005-04-07 | ブリストル−マイヤーズ スクイブ カンパニー | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators |
AU2003202115A1 (en) * | 2002-02-12 | 2003-09-04 | Pfizer Inc. | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
US20080261918A1 (en) * | 2004-12-17 | 2008-10-23 | Graham Andrew Showell | Silicon Compounds and Their Use |
-
2006
- 2006-09-07 BR BRPI0615631-2A patent/BRPI0615631A2/en not_active IP Right Cessation
- 2006-09-07 EA EA200800780A patent/EA200800780A1/en unknown
- 2006-09-07 MX MX2008002294A patent/MX2008002294A/en active IP Right Grant
- 2006-09-07 EP EP06846967A patent/EP1937653A1/en not_active Withdrawn
- 2006-09-07 UA UAA200803570A patent/UA93387C2/en unknown
- 2006-09-07 KR KR1020087004306A patent/KR20080043314A/en not_active Application Discontinuation
- 2006-09-07 ZA ZA200802174A patent/ZA200802174B/en unknown
- 2006-09-07 AU AU2006322461A patent/AU2006322461A1/en not_active Abandoned
- 2006-09-07 CA CA002621854A patent/CA2621854A1/en not_active Abandoned
- 2006-09-07 WO PCT/DK2006/050039 patent/WO2007065449A1/en active Application Filing
- 2006-09-07 JP JP2008529473A patent/JP2009507052A/en not_active Withdrawn
- 2006-09-07 CN CNA2006800327125A patent/CN101258133A/en active Pending
- 2006-09-08 AR ARP060103924A patent/AR055420A1/en not_active Application Discontinuation
-
2008
- 2008-02-14 IL IL189545A patent/IL189545A0/en unknown
- 2008-04-09 NO NO20081713A patent/NO20081713L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20080043314A (en) | 2008-05-16 |
AR055420A1 (en) | 2007-08-22 |
WO2007065449A1 (en) | 2007-06-14 |
UA93387C2 (en) | 2011-02-10 |
IL189545A0 (en) | 2008-06-05 |
BRPI0615631A2 (en) | 2011-05-24 |
EP1937653A1 (en) | 2008-07-02 |
CN101258133A (en) | 2008-09-03 |
CA2621854A1 (en) | 2007-06-14 |
ZA200802174B (en) | 2009-10-28 |
JP2009507052A (en) | 2009-02-19 |
NO20081713L (en) | 2008-06-04 |
EA200800780A1 (en) | 2008-06-30 |
AU2006322461A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2008002294A (en) | Pyrimidine derivatives and their use as kcnq potassium channels openers. | |
TW200800968A (en) | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | |
WO2007027238A3 (en) | Jak kinase inhibitors and their uses | |
TW200630367A (en) | Substituted adenines and the uses thereof | |
MX2010004576A (en) | Novel pyrimidine derivatives. | |
SG164368A1 (en) | Treatment of cancer | |
WO2010090860A3 (en) | Methods and compositions for treating bacterial infection | |
UA102251C2 (en) | Aminidihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease | |
TW200624426A (en) | BACE inhibitors | |
EA200970575A1 (en) | COMPOUNDS ON THE BASIS OF 4-PHENYL-6- (2,2,2-TRIFTOR-1-PHENYLETOXI) Pyrimidine and methods for their use | |
UA85559C2 (en) | Aminobenzophenone compounds | |
WO2009077471A3 (en) | Azolylmethyloxiranes, use thereof and agents containing the same | |
WO2006072612A3 (en) | Triazolophthalazines as pde2- inhibitors | |
ZA200802848B (en) | Potassium channel inhibitors | |
WO2007067559A3 (en) | Antibacterial agents | |
UA90698C2 (en) | Triazole substituted aminobenzophenone compounds | |
MX2009007713A (en) | Pyridazine derivatives, processes for their preparation and their use as fungicides. | |
MX2009013515A (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics. | |
WO2007097981A3 (en) | Alpha carbolines and uses thereof | |
MX2011005425A (en) | Lantibiotic carboxyamide derivatives with enhanced antibacterial activity. | |
WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
TW200726763A (en) | Novel compound | |
MX2010009276A (en) | Pyrrolopyrimidinecarboxamides. | |
MX2009009490A (en) | Novel prodrugs. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |